Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
McKesson
US Army
McKinsey
UBS
Baxter
QuintilesIMS
Chubb
Accenture

Generated: February 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ACETAZOLAMIDE

« Back to Dashboard

Clinical Trials for Acetazolamide

Trial ID Title Status Sponsor Phase Summary
NCT00000115 Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema Completed National Eye Institute (NEI) Phase 2 To test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid macular edema.
NCT00004802 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders Completed Ohio State University Phase 3 OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00004802 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders Completed National Center for Research Resources (NCRR) Phase 3 OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00108602 Sleep Apnea: Mechanism and Cerebrovascular Consequences Withdrawn VA Office of Research and Development N/A This study will determine the effect of ventilatory stimulation on obstructive sleep apnea in selected patients with stroke. We will select a subset of patients with stroke in the prior 3 months who are most likely to have ventilatory instability as a cause of the upper airway obstruction as indicated by the absence of obesity, an abnormal hypocapnic apnea threshold and resolution of obstructive apnea during CO2 administration. Following baseline polysomnography, patients will be randomly assigned to acetazolamide (250 mg hs [at bedtime]) versus placebo for 7 days. Polysomnography will be repeated and then subjects will cross-over therapies for another 7 days followed by a final nocturnal polysomnography.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Acetazolamide

Condition Name

Condition Name for Acetazolamide
Intervention Trials
Acute Mountain Sickness 7
Altitude Hypoxia 7
Chronic Obstructive Pulmonary Disease 6
Heart Failure 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Acetazolamide
Intervention Trials
Altitude Sickness 23
Lung Diseases 10
Pulmonary Disease, Chronic Obstructive 10
Sleep Apnea Syndromes 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Acetazolamide

Trials by Country

Trials by Country for Acetazolamide
Location Trials
United States 82
Kyrgyzstan 16
Israel 6
Canada 6
Switzerland 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Acetazolamide
Location Trials
California 7
Massachusetts 6
New York 6
Texas 5
Ohio 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Acetazolamide

Clinical Trial Phase

Clinical Trial Phase for Acetazolamide
Clinical Trial Phase Trials
Phase 4 36
Phase 3 9
Phase 2/Phase 3 5
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Acetazolamide
Clinical Trial Phase Trials
Recruiting 36
Completed 34
Not yet recruiting 9
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Acetazolamide

Sponsor Name

Sponsor Name for Acetazolamide
Sponsor Trials
University of Zurich 21
National Center of Cardiology and Internal Medicine, Kyrgyzstan 16
Rabin Medical Center 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Acetazolamide
Sponsor Trials
Other 140
NIH 11
U.S. Fed 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Argus Health
McKesson
Colorcon
Cerilliant
Fuji
QuintilesIMS
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.